Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Not photodynamic therapy
View:
Post by Eoganacht on Aug 22, 2024 10:20am

Not photodynamic therapy

To state the obvious, if Metaformin can successfully activate Rutherrin to produce ROS and selectively kill cancer cells then Theralase has left the realm of photodynamic therapy and joined the mainstream medical treatment world of needle sticking and pill popping. 

This should make at least some of Theralase's ACT more appealing to big pharma. If, in some futute procedure, patients aren't completely cancer free after taking their Rutherrin/Metaformin then doctors can freshen up the effect with a light dose of X-rays which are a pretty mainstream cancer treatment already.

The fact that both drugs can cross the blood-brain barrier might effect the design of the upcoming gbm trial by adding Metaformin to the Rutherrin, X-ray mix.
Comment by enriquesuave on Aug 22, 2024 10:42am
This could potentially be beyond huge!  We see that the combination of Rutherin and Metformin results in the same ROS formation as Rutherin and X-rays alone.  Basically what that would allow is for treatment of main tumors with Combination Ruherin-Metformin and X-rays for even greater ROS formation and tumor cell kill, and at the same time, any distant or undetected metastasis would be ...more  
Comment by DJDawg on Aug 22, 2024 10:48am
Eog. I have a science question as I don't understand all the nuances of PDT. When light activates a Ru compound such as ruvidar or rutherrin is the light part of the energy transfer process leading to ROS and cell damage or is it more that the compounds are like coiled springs, ready to help generate ROS with the right trigger event? I ask only because the metformin activation makes you think ...more  
Comment by Eoganacht on Aug 22, 2024 12:18pm
Hi DJDawg - that's a toughie. I'm afraid the science behind PS activation is beyond me but Dr. McFarland investigated this and reported about it in a 2023 paper. Using Biological Photophysics to Map the Excited-State Topology of Molecular Photosensitizers for Photodynamic Therapy Abstract ...Very little is known about the excited-state properties of any PS in live cells, and for TLD1433 ...more  
Comment by Eoganacht on Aug 22, 2024 6:16pm
Also Drs. McFarland, Lilge and colleaguea went into some detail about the mechanism of PS activation in their 2019 paper: Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433 "The mechanisms of the photodynamic effect (and hence PDT) are inherently complex, but they generally fall into ...more  
Comment by DJDawg on Aug 22, 2024 6:21pm
Thanks for sharing. So interesting and complicated. I cannot say I get most of it but the more I read the more I get.
Comment by CancerSlayer on Aug 22, 2024 12:55pm
Great post Eoganacht.  The ramifications of the Rutherrin-Metformin combo continue to grow/surprise.   I guess the number of combo treatments will depend on the half-life or clearance rate of these drugs in order to determine appropriate at home use.  But even if Rutherrin &/or x-ray radiation are required more often, this would not exclude their use at home.  For the sick ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250